ICPT likely to gap below 250 on monday, here is why:
ICPT gave out the impression that the phase 2 trial was stopped early & fast track early approval coming. NIH came out and said safety side effects. This at the very least means ICPT will need to run a phase 3 trial. All of today's gains will be gone by Monday morning.